The Role of CSF in Chiari II Brain Malformation

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 1
SponsorUniversity College, London

About this trial

Spina bifida, particularly its most severe form known as open spina bifida (myelomeningocele), is a significant congenital disorder that results in profound neurological impairments, including Chiari II malformation. This malformation is associated with the downward displacement of the cerebellum and brainstem into the spinal canal, often leading to hydrocephalus, a condition where cerebrospinal fluid (CSF) accumulates in the brain1. These conditions can result in a range of complications, including cognitive and motor disabilities, learning difficulties, and, in severe cases, early mortality1,2.

While surgical interventions, including prenatal and postnatal surgeries, have been developed to manage the physical manifestations of spina bifida and Chiari II malformation, these procedures have not been fully successful in addressing the associated brain anomalies3. This study aims to explore the hypothesis that the composition of CSF plays a critical role in the development of these brain defects. Specifically, it is hypothesized that the rapid replenishment of CSF, due to its leakage from the open spine in spina bifida, results in a "less mature" fluid composition, which negatively affects neurogenesis and neuronal migration during critical periods of brain development.

Eligibility criteria

Qualifiers

Diagnosed with open spina bifida (myelomeningocele).

Scheduled for postnatal surgical closure of the spinal lesion at Great Ormond Street Hospital (GOSH).

Age: Between 1 day to 1 year old.

Newborns scheduled for shunt surgery for hydrocephalus unrelated to spina bifida.

Disqualifiers

Newborns who have undergone previous surgical intervention.

Presence of additional unrelated congenital anomalies that could affect cerebrospinal fluid (CSF) composition like meningitis or intraventricular bleeding

Older than 1 year and 1 month of age.

Parents refused to participate

Trial design

Treatments tested in this trial

  • collection of cerebrospinal fluid

Treatment groups

18 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Locations

This trial has no locations

Sponsors and collaborators

University College, London

Lead sponsor

Great Ormond Street Hospital for Children NHS Foundation Trust

Collaborator

University College London Hospitals

Collaborator